Anticorps Monoclonal anti-VEGFR2/KDR
VEGFR2/KDR Monoclonal Antibody for WB, ELISA
Hôte / Isotype
Mouse / IgG1
Réactivité testée
Humain
Applications
WB, IHC, IF, ELISA
Conjugaison
Non conjugué
CloneNo.
1G2A8
N° de cat : 67407-1-Ig
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | tissu placentaire humain, |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:8000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| WB | See 7 publications below |
| IHC | See 1 publications below |
| IF | See 3 publications below |
| FC | See 1 publications below |
Informations sur le produit
67407-1-Ig cible VEGFR2/KDR dans les applications de WB, IHC, IF, ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | Humain |
| Hôte / Isotype | Mouse / IgG1 |
| Clonalité | Monoclonal |
| Type | Anticorps |
| Immunogène | VEGFR2/KDR Protéine recombinante Ag24589 |
| Nom complet | kinase insert domain receptor (a type III receptor tyrosine kinase) |
| Masse moléculaire calculée | 1356 aa, 152 kDa |
| Poids moléculaire observé | 230 kDa |
| Numéro d’acquisition GenBank | BC131822 |
| Symbole du gène | KDR |
| Identification du gène (NCBI) | 3791 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine G |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
KDR, also named as VEGFR-2, FLK1 and CD309, is a receptor for VEGF or VEGFC. KDR which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for VEGFR2/KDR antibody 67407-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Front Genet ANLN and KDR Are Jointly Prognostic of Breast Cancer Survival and Can Be Modulated for Triple Negative Breast Cancer Control. | ||
Arch Pharm (Weinheim) Design, synthesis, and biological evaluation of naphthalene imidazo[1,2-b]pyridazine hybrid derivatives as VEGFR selective inhibitors | ||
Adv Mater Personalized Vascularized Tumor Organoid-on-a-Chip for Tumor Metastasis and Therapeutic Targeting Assessment | ||
Cell Tissue Res A histological study of vascular wall resident stem cells in venous malformations |
